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Several lines of evidence point to the involvement of inflammation and white matter (WM) damage in early AD disease progression. First, cognitively normal individuals who chronically use non-steroidal anti-inflammatories have fewer activated microglia and lower risk of AD than non-users (Andersen et al., 1995; Broe et al., 2000; Cote et al., 2012) . Fibrillar Aβ stimulates a classical proinflammatory response in microglia, which can be visualized in AD patients and may be present in preclinical AD (Bradshaw et al., 2013; Serrano-Pozo et al., 2013; Ulrich et al., 2018) . A study of autosomal dominant AD suggested that astrocyte activation occurs in presymptomatic AD, indicating that inflammatory astrocytosis may contribute to early symptomatic AD pathology (Scholl et al., 2015) . Moreover, disrupted WM may occur very early in preclinical AD (Heise et al., 2011; Molinuevo et al., 2014; Racine et al., 2014) , promote A C C E P T E D M A N U S C R I P T 5 phagocytosis of amyloid plaques (Smith et al., 2007a; Stokin et al., 2005) , and modulate the relationship between the pathological and clinical manifestations of AD (Salat et al., 2009) .
Animal studies have recently demonstrated defective clearance of myelin debris, axonal dystrophy, and oligodendrocyte reduction in the triggering receptor expressed on myeloid cell 2 (TREM2) (a microglial immunoreceptor) -deficient mice compared to wild-type mice (Cantoni et al., 2015; Poliani et al., 2015) , suggesting microglial response to WM damage. These findings have led to a search for accurate and robust in vivo markers specific for inflammation and WM damage in AD.
A novel multi-parametric diffusion MRI analytic technique, diffusion basis spectrum imaging (DBSI), was developed to simultaneously detect and quantify inflammation and WM damage in the central nervous system. In particular, DBSI can discretely quantify intra-and extracellular water and allows for discrimination of vasogenic edema, increased cellularity, axonal injury/loss, and demyelination (Chiang et al., 2014; Wang et al., 2014; Wang et al., 2011; Wang et al., 2015) . The DBSI biomarker for inflammation is the DBSI restricted water compartment, which is a surrogate for cellularity. DBSI cellularity increases have been associated with activated microglia and astrogliosis in multiple sclerosis (Chiang et al., 2014; Wang et al., 2014; Wang et al., 2011; Wang et al., 2015) ; therefore, it can be potentially employed as a marker for astrogliosis and microglial activation in AD. Moreover, DBSI can separate anisotropic diffusion markers (reflecting white matter integrity) from isotropic diffusion markers, and are thus more specific and accurate in reflecting WM pathology than the standard model of diffusion tensor imaging (DTI) (Chiang et al., 2014; Wang et al., 2014; Wang et al., 2011; Wang et al., 2015) . As initially conceived, DBSI employed diffusion MRI scans with 99 diffusion weightings. This protocol is not always available or optimal in clinical or clinical
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A C C E P T E D M A N U S C R I P T 6 research settings. In the previous simulation and ex vivo study (Chiang et al., 2014) , a compact 25-direction diffusion MRI scan provided sufficient accuracy in DBSI solutions. Here, we use the same 25-direction, multiple b value diffusion MRI version of DBSI; We denote this clinical version of DBSI as neuro-inflammation imaging (NII). NII was used to study healthy cognitively normal controls, participants with preclinical (asymptomatic) AD, and participants with early symptomatic AD to better understand the role of WM inflammation and degeneration in the pathogenesis and progression of AD. The association between NII-derived indices and CSF biomarkers of AD pathology were examined to assess the relationship between WM inflammation, damage and AD amyloid and tau pathologies.
Materials and Methods

Participants
Two hundred participants were enrolled in longitudinal clinical and biomarker studies of memory and aging at the Knight Alzheimer Disease Research Center at Washington University School of Medicine (St Louis, MO, USA) (P50AG005681, P01AG026276, and P01AG003991).
Details of recruitment and assessment have been published elsewhere (Berg et al., 1998) . The Human Research Protection Office at Washington University approved all studies, and written informed consent was obtained from all participants. All individuals were evaluated by experienced clinicians using a semi-structured interview with a knowledgeable collateral source.
Detailed neurological examinations of the participants were performed in accordance with the Uniform Data Set protocol of the National Alzheimer's Coordinating Center (Morris et al., 2006) . A clinical diagnosis of symptomatic AD, where appropriate, was made in accordance with criteria developed by working groups from the National Institute on Aging and the Alzheimer's Association (Albert et al., 2011; McKhann et al., 2011) . Dementia was staged according to the
global Clinical Dementia Rating (CDR) (Morris, 1993) . The inclusion criteria required participants have CSF measures of amyloid (Aβ42) and neurodegeneration (total tau [t-tau]) within two years of the MRI acquisition; Participants were classified as healthy controls (n=140) if they were AD biomarker negative (CSF Aβ42 ≥ 459 pg/ml and t-tau < 339 pg/ml) as defined previously (Vos et al., 2013) and cognitively normal defined as a CDR = 0 (Morris, 1993) .
Participants were classified as preclinical AD (n=34) according to NIA-AA criteria (Sperling et al., 2011) if they had positive CSF Aβ42 (CSF Aβ42 < 459 pg/ml) with normal cognition (CDR = 0). Early symptomatic AD participants (n=26) had very mild dementia (CDR=0.5), positive CSF Aβ42 (CSF Aβ42 < 459 pg/ml) and these participants were diagnosed with dementia thought to be due to AD without other disease contribution (e.g., depression, cerebrovascular disease, etc.) (McKhann et al., 2011) . Other neuropsychological evaluations including the Mini-Mental Stage Exam (MMSE) and CDR sum of boxes were also provided.
Genotyping
DNA was extracted from peripheral blood samples by standard procedures.
Apolipoprotein E genotyping was performed as previously described (Talbot et al., 1994) . The presence of at least one apolipoprotein E ε4-allele was defined as APOE ε4 positive (APOE ε4+).
CSF collection and analysis
CSF (20-30 mL) was collected within 24 months of the imaging session by routine lumbar puncture using a 22-gauge atraumatic Sprotte spinal needle (Pajunk Medical Systems, Norcross, GA, USA) after overnight fasting as previously described (Fagan et al., 2006) . Samples were gently inverted to avoid possible gradient effects, briefly centrifuged at low speed, aliquoted (0.5 mL) into polypropylene tubes, and frozen at −84°C. Samples were analyzed by ELISA for Aβ42 and t-tau (INNOTEST; Fujirebio, formerly Innogenetics, Ghent, Belgium).
MRI Acquisition
Diffusion MRI was collected on 3T TIM Trio (Siemens, Erlangen, Germany) scanners with a 12-channel head coil equipped with parallel imaging. The imaging resolution was 2×2×2 
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Data processing and analysis
The 25 diffusion-weighted images acquired in one diffusion MRI sequence were motioncorrected by an iterative procedure. In order to correct for eddy current related geometric distortion between EPI diffusion images and 3D GRE/FSE anatomical images, we first registered the non-b0 diffusion images to b0 images with rigid body transformation. Then a 9-parametric affine transformation was employed to correct for stretch along the phase encode direction to better align the b0 image to the T2W image. Registration was completed by aligning the T2W images to the T1W images which were then aligned with the atlas image. The final resampling step output 24 volumes registered with the B0 volume of the first acquired diffusion-weighted imaging dataset. The two runs were averaged together to obtain a better signal-to-noise ratio. All datasets were analyzed by a multi-tensor model analysis package developed in-house in Matlab (MathWorks) (Wang et al., 2011) and maps of NII cellular fraction, cellular diffusivity, FA, axial, radial and mean diffusivities were generated.
The whole-brain, voxel-wise NII-derived indices were analyzed using Tract Based Spatial Statistics (TBSS) (Smith et al., 2007b; Smith and Nichols, 2009 ) (FSL, http://www.fmrib.ox.ac.uk/fsl). NII FA images were slightly eroded, so the boundary image
slices were excluded to remove possible outliers caused by poor diffusion tensor fitting at the edges. Participants' FA data were aligned into a common space using the nonlinear registration tool FNIRT (Jenkinson et al., 2002) . A mean FA image was created and thinned to create a mean FA skeleton that represents the centers of all tracts common to the group. Each participant's aligned FA data, and other NII-derived indices, were projected onto this skeleton for statistical analyses. Nonparametric permutation tests were used for voxel-wise statistical analysis of the individual FA skeletons between the healthy controls, the preclinical AD and the early symptomatic AD cohorts. Voxel-wise associations between NII-derived indices and CSF markers of AD pathologies (CSF Aβ42 and t-tau) were examined through TBSS. The significance threshold for group differences and associations with CSF biomarkers was set at P < 0.05, corrected for multiple comparisons by using a family-wise error correction across voxels by using the threshold-free cluster-enhancement option in Randomise 2.0 in FSL (Smith and Nichols, 2009 ). Identification of the abnormal WM tracts revealed by TBSS was based on the Johns Hopkins University (JHU) atlas (Hua et al., 2008; Mori and van Zijl, 2007; Wakana et al., 2004; Wakana et al., 2007) . The statistical analyses performed by TBSS controlled for age, gender, and the presence of an APOE 4 allele.
Continuous and categorical variables in characteristics across all the three groups were compared using the Kruskal-Wallis test and the Chi-square test, respectively. The least square means per group for each outcome were estimated after controlling for age, gender and APOE 4
genotype. The partial correlation was also considered to measure the strength of a relationship between CSF measures and imaging metrics in WM tracts while controlling for the effects of other variables. All statistical tests were two-sided with α = 0.05. SAS version 9.4 (Cary, NC) was used to perform all statistical analyses.
A C C E P T E D M A N U S C R I P T
Results
Participant demographics
Demographic data are summarized in Table 1 . Our cohort included 140 cognitively normal healthy control participants (CSF biomarker-negative), 34 cognitively normal individuals with preclinical AD (CSF Aβ42-positive), and 26 participants with early symptomatic AD (CDR = 0.5) (CSF Aβ42-positive). On average, the early symptomatic AD individuals were significantly older than the healthy controls and preclinical AD individuals, and the early symptomatic AD group included more male participants than the other two cohorts. Only 12.9% of the healthy controls carried at least one APOE 4 allele, whereas 76.5% of the preclinical AD and 88.5% of the early symptomatic AD participants carried this allele. MMSE and CDR sum of box measures for early symptomatic AD were significantly higher than those in the healthy controls and preclinical AD group. The CSF level of Aβ42 in the healthy controls was Data are presented as mean (SD) or number (%). Healthy controls: participants with ≥ 459 pg/ml Aβ42 and ≤ 339 pg/ml total tau in the cerebrospinal fluid (CSF) and with normal cognition (CDR=0). Preclinical AD: participants with < 459 pg/ml Aβ42 in the CSF and with normal cognition (CDR=0). Early symptomatic AD: participants with < 459 pg/ml Aβ42 in the CSF and with very mild AD dementia (CDR=0.5). APOE 4 +, positive for at least one apolipoprotein E ε4-allele. MMSE: Mini-Mental State Exam.
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NII cellular fraction in the preclinical and early symptomatic AD
No voxel-wise statistical differences of the NII cellular fraction (reflecting cell density)
were found among the healthy controls, the preclinical and the early symptomatic AD cohorts.
As an example, the averaged NII cellular fraction in the region of genu of corpus callosum is 4.5% (±1.1%) for the healthy controls, 4.5% (±0.8%) for the preclinical AD and 4.4% (±1.3%)
for the early symptomatic AD.
NII cellular diffusivity in the preclinical and early symptomatic AD
Elevated NII cellular diffusivity (reflecting cell size) was observed in the preclinical AD cohort when compared to the healthy controls in the major WM tracts including corpus callosum, internal capsule, corona radiata and cingulum etc. (Fig. 1A) . NII cellular diffusivity was also significantly increased in the early symptomatic AD cohort when compared to those in the preclinical AD in some major WM tracts (Fig. 1B) . As an example, the significant voxels common to all participants in the genu of corpus callosum were extracted to demonstrate significantly increasing NII cellular diffusivity in the preclinical AD when compared to the healthy controls, and the further increasing of this index in the early symptomatic AD cohort (P
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A C C E P T E D M A N U S C R I P T 14 < 0.05) (Fig. 1C) . Similar findings were also found in other white matter tracks and summarized in Supplementary Table 1. Relationship between NII biomarker of inflammation and CSF biomarker of amyloid plaque NII cellular diffusivity was negatively correlated with CSF levels of Aβ42 in major WM tracts ( Fig. 2A and Supplementary Table 2 ) when analyzed across all groups. The mean NII cellular diffusivity from the cluster located in the genu of corpus callosum were extracted. As an estimate of effect size, the partial correlations were also examined between NII imaging markers and CSF Aβ42. When controlling with age, gender and APOE 4 genotype, the partial correlation with CSF Aβ42 was rpartial = 0.39 (P < 0.001) for NII cellular diffusivity.
NII-derived FA, axial, radial and mean diffusivities in the preclinical and early symptomatic AD
A significant voxel-wise decrease of NII FA was found in the early symptomatic AD cohort when compared to the healthy controls and the preclinical AD cohorts in most of the WM tracts ( Fig 3A&B and Supplementary Table 1 ). The significant voxel-wise increase of NII radial diffusivity, which is a more accurate measure of the myelination than its DTI-derived counterpart (Wang et al., 2011; Wang et al., 2015) , was also found in the early symptomatic AD cohort when compared to the healthy controls and the preclinical AD cohorts in most of the WM tracts ( Fig   3C&D and Supplementary Table 1 ). There were no differences of NII FA and radial diffusivity between the healthy controls and the preclinical AD cohorts. The significant voxels common to all participants in the genu of corpus callosum were extracted to demonstrate there were a significant decrease of NII-derived FA (Fig. 3E .a) and a significant increase of NII radial diffusivity ( Fig. 3E .b) in the early symptomatic AD cohort when compared to the healthy controls and the preclinical AD cohorts (P < 0.05). No differences were found among the three cohorts for NII axial and mean diffusivities.
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Green: The mean FA skeleton; Yellow: significant positive correlation, P < 0.05 after multiple comparison; Red: expanded to be visible. 
E. Quantification of NII-derived FA and radial diffusivity in the Genu
Relationship between NII-derived indices and CSF t-tau
A significant negative relationship was found between CSF levels of t-tau and NII FA in WM ( Fig. 4A and Supplementary Table 2) . No other NII-derived indices were associated with CSF levels of t-tau. The partial correlations as a measure of effect size were also examined between NII FA and CSF tau in those voxels that were significant in the splenium of corpus callosum. When controlling for age, gender and APOE 4 genotype, the partial correlation with CSF t-tau was rpartial = 0.33 (P <0.001) for NII FA. Immune cells, particularly microglia and astrocytes, have been reported to mediate the inflammatory response in AD and are considered a significant contributor to AD pathogenesis.
Detecting and quantifying the early neuroinflammation manifested in AD as immune cell activation and infiltration could shed light on potential mechanisms underlying AD pathogenesis and progression. Based on the previous success of DBSI (Chiang et al., 2014; Wang et al., 2014; Wang et al., 2011; Wang et al., 2015) , NII was developed and implemented on clinical scanners to simultaneously detect and quantify WM cellularity change, which may reflect inflammation and WM damage, and their associations with CSF measures of AD pathologies in preclinical and early symptomatic AD. (Edison et al., 2008) . However, these PET approaches are limited by issues including binding tied to genetic polymorphisms (Owen et al., 2011; Owen et al., 2012) , lackingspecificity of translocator protein binding for activated microglia (Kreisl et al., 2013; Lavisse et al., 2012) and variability of plasma protein binding (Turkheimer et al., 2015) . Additionally, most of the
current TSPO PET tracers are [ 11 C] based and can only be performed at academic centers in proximity to a research cyclotron facility (Fan et al., 2015; Varley et al., 2015) . Elevated levels of CSF YKL40 (Craig-Schapiro et al., 2010) and other proteins have also been reported to be markers of inflammation (Alcolea et al., 2015; Heppner et al., 2015; Wilkins et al., 2015) .
Astroglial activation suggested by the elevated CSF levels of YKL40 has been observed in preclinical AD, mild cognitive impairment and early AD (Alcolea et al., 2015; Antonell et al., 2014; Craig-Schapiro et al., 2010; Olsson et al., 2013) . CSF levels of YKL40 are promising in discriminating between cognitively normal individuals and patients with mild cognitive impairment (MCI) and AD, and in predicting the progression of cognitively normal individuals to MCI (Kester et al., 2015) . However, CSF analyses have limitations including potential assay drift (Schindler et al., 2018) , inter-laboratory variability in measurements of certain markers (Mattsson et al., 2010; Mattsson et al., 2011; Mattsson et al., 2013) , the invasiveness of a lumbar puncture and an inability to provide information about the anatomic location of pathology (Zetterberg, 2015) . Given these limitations, as a non-invasive, non-radioactive imaging technique capable of quantifying cellular alterations which may reflect inflammation in the general population, NII holds a unique position to potentially advance our understanding of the role of inflammation in pre-symptomatic and early symptomatic AD.
In the present study, the lack of statistical difference of the NII cellular fraction among healthy controls, preclinical and early symptomatic AD suggests that there is no increase in inflammatory cell fraction (whether from proliferation or infiltration) in preclinical and early symptomatic AD. Microglia/astrocyte activation involves a rapid alteration of cellular metabolism and function, which can be accompanied by a graded spectrum of morphological changes that transform highly ramified microglia/astrocytes into amoeboid-phagocytic
microglia/astrocytes with an increase in cell body size (Iaccarino et al., 2016; Soltys et al., 2001; Torres-Platas et al., 2014) . A few diffusion MRI techniques have demonstrated their sensitivity to fiber or cell diameters by tracking the changes of water diffusion (Alexander et al., 2010; Barazany et al., 2009; Schachter et al., 2000; Stanisz et al., 1997) . Increased cellular diffusivity which would be correspond with an increase in cell body size may serve as a potential marker for microglia/astrocyte activation in AD. In this study, NII derived cellular diffusivity was quantified in each group to reflect the extent of activated microglia/astrocytes. The observed increase of NII cellular diffusivity ( 
